Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer

References

• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351: 2519–29
   PubMed Web of Science ®Google Scholar
• du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annal Oncol. 2005; 16 Suppl 8: 7–12
   Web of Science ®Google Scholar
• Kawanagh JJ, Pecorelli S, Benedet JL. Cancer of the ovary. In: Benedet JL, Hacker NF, Ngan HYS. Staging classification and clinical practice guidelines of gynaecologic cancers by FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2nd edn. SantiagoChile: Ushers Print & Design, 2003. pp. 92–118.
   Google Scholar
• Hofstra LS, de Vries EG, Mulder NH, Willemse PH. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev. 2000; 26: 133–43
   PubMed Web of Science ®Google Scholar
• Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, et al. Long-term survival of advanced refractory ovarian carcinoma patients treated with small volume disease treated with intraperitoneal chemo-therapy. J Clin Oncol. 1987; 5: 1607–12
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T, Lewis JL, Jr., Jones W, Rubin S, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarin cancer. J Clin Oncol. 1992; 10: 1479–84
   PubMed Web of Science ®Google Scholar
• de Jong RS, Willemse PH, Boonstra H, de Vries EG, van der Graaf WT, Sleijfer DT, et al. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual disease. Eur J Cancer. 1995; 31: 709–13
   Web of Science ®Google Scholar
• Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, et al. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol. 1989; 7: 1327–32
   PubMed Web of Science ®Google Scholar
• Braly S. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer. A phase II Gynecologic Oncology Group trial. Gynecol Oncol. 1995; 56: 164–8
   PubMed Web of Science ®Google Scholar
• Piver MS, Recio FO, Baker TR, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 1994; 73: 1693–8
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S, et al. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. J Cancer Res Clin Oncol. 1992; 118: 235–7
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Jr., Rubin S, et al. Responses to second line cisplatin based intraperitoneal chemotherapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991; 9: 1801–5
   PubMed Web of Science ®Google Scholar
• Recio FO, Piver MS, Hempling RE, Driscoll DL. Five year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1998; 68: 267–73
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003; 90: 637–43
   PubMed Web of Science ®Google Scholar
• Vermorken JB. The role of intraperitoneal chemotherapy in epithelial ovarian cancer. Int J Gynecol Cancer 2000; 10(Suppl 1): 26–32
   Web of Science ®Google Scholar
• Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol. 2002; 20: 694–8
   PubMed Web of Science ®Google Scholar
• Gadducci A, Conte PF. Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int J Gynecol Cancer. 2008;18:943–53.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 34–43
   PubMed Web of Science ®Google Scholar